Should You Buy, Sell or Hold Trupanion Stock Post Q2 Earnings?

Shares of TRUP have gained 14.4% in the past three months, outperforming its industry, sector and the Zacks S&P 500 composite, in the same time frame.   

TRUP vs Industry, Sector, S&P 500

Image Source: Zacks Investment Research

Shares of Lemonade Inc. LMND, another seller of pet insurance, have lost 5.7% in the past three months while those of Root Inc. ROOT, a technology-oriented insurance company seeking growth through specialized underwriting and digital customer acquisition, have lost 10.4% in the same time frame.

Sneak Peek Into TRUP’s Q2 Results

TRUP generated $393 million of revenues, up 11% year over year and beat the consensus estimate by 0.8%.

Total enrolled pets (including pets from our other business segment) were 1.6 million as of June 30, 2026, a decrease of 2% year over year. Subscription enrolled pets were 1.1 million as of June 30, 2026, an increase of 5% year over year. 

Subscription business revenues were $276.7 million, up 14% year over year.

Total expenses were $58.7 million, up 12% year over year.

Adjusted EBITDA was $19.8 million, up from $16.6 million in the second quarter of 2025. 

The bottom line came in at 16 cents, beating the estimate by 45% but declining 27% year over year.

Operating cash flow was $21 million and free cash flow was $19.2 million in the second quarter.

In July 2026, the New York Department of Financial Services approved an extraordinary dividend of $44 million to be paid to Trupanion by its wholly-owned subsidiary, American Pet Insurance Company.  

The board also approved a $100 million share buyback program.

Cautious Guidance

For 2026, TRUP expects total revenues in the range of $1.584 billion to $1.601 billion. Subscription revenues are now expected to be between $1.124 billion and $1.133 billion. The midpoint of the range has increased slightly and continues to represent approximately 14% year-over-year growth. The insurer also narrowed the total adjusted operating income range to be between $176 million and $184 million, or19% year-over-year growth at the midpoint.

For the third quarter of 2026, total revenues are expected to be in the range of $399 million to $405 million. Subscription revenues are expected to be between $284 million and $287 million, representing approximately 13% year-over-year growth at the midpoint. Total adjusted operating income is expected to be in the range of $44 million to $47 million. This represents approximately 11% growth year over year at the midpoint.

TRUP Shares Are Expensive

The stock is overvalued compared with its industry. It is currently trading at a price-to-book multiple of 3.11, higher than the industry average of 1.86 but lower than the median of 4.28 over the past three years. It has a Value Score of C.

Image Source: Zacks Investment Research

TRUP shares are more expensive than ROOT but cheaper than LMND.

The Case for TRUP Stock

Trupanion has built a differentiated business model centered on high customer retention, recurring subscription revenues and a proprietary technology platform. A key competitive advantage is its direct-pay software, which allows participating veterinary hospitals to receive claim payments at checkout, enhancing the customer experience and strengthening veterinary relationships.

The company continues to benefit from strong monthly retention, a growing base of enrolled pets, and higher average revenue per pet (ARPU), driving consistent mid-teens revenue growth. With veterinary care costs rising faster than consumer discretionary income, effective pricing remains critical to sustaining growth while ensuring pet owners can continue to access quality care.

International expansion is another important growth driver. As part of its five-year strategy, Trupanion has expanded its presence in Europe, where pet insurance penetration remains relatively low, creating a significant long-term growth opportunity. A larger subscriber base should also improve operating leverage, supporting margin expansion and stronger free cash flow over time.

To broaden its addressable market, the company is expanding its product portfolio with offerings such as Chewy and Aflac, which target lower- and mid-ARPU segments, alongside Firkin, Phi Direct, and products tailored for continental Europe. Trupanion has also introduced a branded offering built on its technology platform and partnered with automation providers in Germany and Switzerland to enhance operational efficiency.

Supported by a strong capital position and solid operating performance, Trupanion is well positioned to invest in product innovation and international expansion, reinforcing its competitive moat and long-term growth prospects.

Mixed Analyst Sentiment on TRUP

The Zacks Consensus Estimate for 2026 revenues and earnings indicates year-over-year improvement of 9.9% and 22.2%, respectively. The consensus estimate for 2027 revenues and earnings indicates year-over-year improvement of 8.1% and 25.2%, respectively. TRUP has a Growth Score of B. 

Image Source: Zacks Investment Research

The consensus estimate for 2026 earnings has moved up 1 cent while that for 2027 has moved down 3 cents in the last 30 days.

The consensus estimates for LMND’s 2026 and 2027 earnings have witnessed southbound movement in the last 30 days. The consensus estimates for ROOT’s 2026 and 2027 earnings have witnessed no movement in the last 30 days.

Parting Thoughts on TRUP Shares

TRUP is poised to grow in the fast-growing pet insurance market as pet ownership continues to increase and veterinary care costs rise.  Its VGM Score of B instills confidence.

Given its premium valuation, muted analyst sentiment and narrowed guidance by management, it is better to adopt a wait-and-see approach for this Zacks Rank #3 (Hold) stock now.  You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.

Zacks' Research Chief Names "Stock Most Likely to Double"

Our team of experts has just released the 5 stocks with the greatest probability of gaining +100% or more in the coming months. Of those 5, Director of Research Sheraz Mian highlights the one stock set to climb highest.

This top pick is a little-known satellite-based communications firm. Space is projected to become a trillion dollar industry, and this company's customer base is growing fast. Analysts have forecasted a major revenue breakout in 2025. Of course, all our elite picks aren't winners but this one could far surpass earlier Zacks' Stocks Set to Double like Hims & Hers Health, which shot up +209%.

Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report

This article originally published on Zacks Investment Research (zacks.com).

Zacks Investment Research